talks with GEN’s Editor-in-Chief John Sterling about tackling bottlenecks in small-molecule drug discovery research.

Previous articlePlexxikon and Roche Ink Cancer Deal, Potentially Worth $700M
Next articlePhiladelphia Court Awarded Plaintiff $1.5M in Prempro Hormone Replacement Case